Axonics, Inc. (NASDAQ:AXNX) Shares Bought by Fmr LLC

Fmr LLC raised its stake in Axonics, Inc. (NASDAQ:AXNX) by 2.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,756 shares of the company’s stock after acquiring an additional 769 shares during the period. Fmr LLC owned 0.06% of Axonics worth $2,210,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of AXNX. Absolute Gestao de Investimentos Ltda. acquired a new position in Axonics in the second quarter valued at $32,681,000. Alpine Associates Management Inc. boosted its stake in Axonics by 16.2% in the second quarter. Alpine Associates Management Inc. now owns 2,108,871 shares of the company’s stock valued at $141,779,000 after acquiring an additional 294,100 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Axonics in the second quarter valued at $15,080,000. Squarepoint Ops LLC boosted its stake in Axonics by 3,961.0% in the second quarter. Squarepoint Ops LLC now owns 190,500 shares of the company’s stock valued at $12,807,000 after acquiring an additional 185,809 shares in the last quarter. Finally, P Schoenfeld Asset Management LP raised its holdings in shares of Axonics by 65.6% in the second quarter. P Schoenfeld Asset Management LP now owns 429,075 shares of the company’s stock valued at $28,847,000 after buying an additional 170,000 shares during the last quarter. Institutional investors and hedge funds own 99.48% of the company’s stock.

Insider Buying and Selling

In related news, CFO Kari Leigh Keese sold 2,961 shares of the stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $69.41, for a total transaction of $205,523.01. Following the completion of the transaction, the chief financial officer now directly owns 40,362 shares of the company’s stock, valued at $2,801,526.42. This represents a 6.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 1.85% of the stock is currently owned by corporate insiders.

Axonics Stock Up 0.8 %

NASDAQ AXNX opened at $70.98 on Friday. The stock has a market capitalization of $3.63 billion, a P/E ratio of -591.45 and a beta of 0.82. Axonics, Inc. has a 52-week low of $55.09 and a 52-week high of $71.05. The firm has a 50-day moving average price of $70.59 and a 200 day moving average price of $69.09.

Analyst Ratings Changes

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Axonics in a report on Friday, November 8th. Eight investment analysts have rated the stock with a hold rating, According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $71.00.

Axonics Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.